Abstract 【Objective】 To investigate the effect of Nicorandil combined with Levosimendan on serum brain natriuretic peptide (BNP), C-reactive protein (CRP) and troponin I (cTnI) levels in patients with ischemic cardiomyopathy and heart failure. 【Methods】The clinical data of 150 patients with ischemic cardiomyopathy with heart failure treated in the Xi'an Fengcheng Hospital were selected and divided into Nicorandil group (group A), Levosimendan group (group B) and Nicorandil combined with Levosimendan group (Group C), with 50 cases in each group. The levels of serum BNP, CRP, cTnI, clinical efficacy and cardiac function [left ventricular end systolic diameter (LVESD), left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), 6 min walking distance] were compared among the three groups after treatment. 【Results】Compared with the group A and the group B, the levels of serum BNP, CRP and cTnI in the group C were significantly lower (P<0.05); There was no significant difference in the levels of serum BNP, CRP and cTnI between the group A and the group B (P>0.05). Compared with the group A and the group B, the group C had significantly lower LVEDD and LVESD, and significantly higher LVEF and 6-min walking distance (P<0.05); There was no significant difference in LVEDD, LVESD, LVEF and 6-min walking distance between the group A and the group B (P>0.05). The total effective rate of the group C was significantly higher than that of the group A and the group B, and the difference was statistically significant (P<0.05). 【Conclusion】 Nicorandil combined with Levosimendan has a good clinical effect in the treatment of ischemic cardiomyopathy with heart failure, which can significantly reduce the levels of serum BNP, CRP and cTnI, and better improve the cardiac function of patients, which is worthy of clinical reference.
ZHANG Wei,LIU Yong-jun. Effect of Nicorandil Combined with Levosimendan on Serum BNP, CRP and cTnI Levels in Patients with Ischemic Cardiomyopathy and Heart Failure[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(7): 1026-1028.
2022, Vol. 39 
